Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Active Filter(s):
Details:
LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist (Testosterone Undecanoate) and α-tocopherol, an antioxidant, is being investigated for the treament of obesity.
Lead Product(s): Testosterone Undecanoate,Vitamin E
Therapeutic Area: Nutrition and Weight Loss Product Name: LPCN 2401
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.
Lead Product(s): Coenzyme Q10,Vitamin E
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Qunol CoQ10
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2023
Details:
Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.
Lead Product(s): Coenzyme Q10,Vitamin E
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Qunol CoQ10
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 27, 2023
